An Open Label Phase I Study Of CP-751,871 In Patients With Multiple Myeloma
Latest Information Update: 07 Nov 2021
Price :
$35 *
At a glance
- Drugs Figitumumab (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Pfizer
- 29 Feb 2012 New trial record